Genezen, a leading gene therapy contract development and manufacturing organization (CDMO), and UF startup Atsena Therapeutics, a clinical-stage gene therapy company focused on using the life-changing power of genetic medicine to reverse or prevent blindness, announced a strategic manufacturing partnership to advance the clinical development and commercial manufacturing of Atsena’s pipeline programs powered by novel adeno-associated virus (AAV) technology engineered to overcome the hurdles presented by inherited retinal diseases. Atsena’s lead program is evaluating ATSN-201 in the pivotal LIGHTHOUSE study for the treatment of X-linked retinoschisis (XLRS) and is on track for a potential Biologics License Application filing in early 2028.
Read more about Genezen and Atsena Therapeutics Announce Strategic Commercial Manufacturing Partnership.
